71
been limited by a few shortcomings such as large size, antigenicity, stability and
cost. Extensive research is ongoing for evolving newer therapeutic enzymes and
also for improvement of the safety and potency of available drugs. Progression in
the latest technology enables manufacturers to make safer and better therapeutic
enzymes.
References
Ali MR, Salim Hossain M, Islam MA, Saiful Islam Arman M, Sarwar Raju G, Dasgupta P, Noshin
TF (2014) Aspect of thrombolytic therapy: a review. Sci World J 2014:586510
Baker SS (2008) Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis. Ther Clin Risk Manag 4:1079–1084
Bayol A, Capdevielle J, Malazzi P, Buzy A, Claude Bonnet M, Colloch N, Mornon JP, Loyaux D,
Ferrara P (2002) Modification of a reactive cysteine explains differences between rasburicase
and Uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem 36:21–31
Beard J (1906) The action of trypsin upon the living cells of jensen’s mouse-tumour. Br Med
J 1:140–141
Bernik MB (1973) Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition. J Clin Invest 52:823–834
Bhagat S, Agarwal M, Roy V (2013) Serratiopeptidase: a systematic review of the existing evidence. Int J Surg 11:209–217
Bijvoet AG, Van Hirtum H, Kroos MA, Van de Kamp EH, Schoneveld O, Visser P, Brakenhoff
JP, Weggeman M, van Corven EJ, Van der Ploeg AT, Reuser AJ (1999) Human acid alphaglucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type
II. Hum Mol Genet 8:2145–2153
Collen D, Van de Werf F (1993) Coronary thrombolysis with recombinant staphylokinase in
patients with evolving myocardial infarction. Circulation 87:1850–1853
Coppola A, Di Capua M, Di Minno MND, Di Palo M, Marrone E, Ieranò P, Arturo C, Tufano
A, Cerbone AM (2010) Treatment of hemophilia: a review of current advances and ongoing
issues. Journal of Blood Medicine 1:183–195
De Duve C (1966) The significance of lysosomes in pathology and medicine. Proceedings of the
Institute of Medicine of Chic 26:73–76
Ea HK, Richette HK (2012) Critical appraisal of the role of pegloticase in the management of gout.
Open Access Rheumatology: Research and Reviews 4:63–70
Elstein D (2011) Recent advances in treatment approaches to gaucher disease. Curr Pharm
Biotechnol 12:854–860
Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2002) Pegylated arginine deiminase (ADI-SS
PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and
in vivo. Cancer Res 62:5443–5450
Falabella AF (2006) Debridement and wound bed preparation. Dermatol Ther 19:317–325
Flohe L (1988) Superoxide dismutase for therapeutic use: clinical experience, dead ends and
hopes. Mol Cell Biochem 84:123–131
Gass J, Ehren J, Strohmeier G, Isaacs I, Khosla C (2005) Fermentation, purification, formulation,
and pharmacological evaluation of a prolyl endopeptidase from Myxococcus xanthus: implications for celiac sprue therapy. Biotechnol Bioeng 92:674–684
Goa KL, Henwood JM, Stolz JF, Langley MS, Clissold SP (1990) Intravenous streptokinase. A
reappraisal of its therapeutic use in acute myocardial infarction. Drugs 39:693–719
Hoffman M, Dargaud Y (2012) Mechanisms and monitoring of bypassing agent therapy. J Thromb
Haemost 10:1478–1485
Honig SC (2014) Intralesional collagenase in the treatment of Peyronie’s disease. Ther Adv Urol
6:47–53
2 Therapeutic Enzymes
been limited by a few shortcomings such as large size, antigenicity, stability and
cost. Extensive research is ongoing for evolving newer therapeutic enzymes and
also for improvement of the safety and potency of available drugs. Progression in
the latest technology enables manufacturers to make safer and better therapeutic
enzymes.
References
Ali MR, Salim Hossain M, Islam MA, Saiful Islam Arman M, Sarwar Raju G, Dasgupta P, Noshin
TF (2014) Aspect of thrombolytic therapy: a review. Sci World J 2014:586510
Baker SS (2008) Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis. Ther Clin Risk Manag 4:1079–1084
Bayol A, Capdevielle J, Malazzi P, Buzy A, Claude Bonnet M, Colloch N, Mornon JP, Loyaux D,
Ferrara P (2002) Modification of a reactive cysteine explains differences between rasburicase
and Uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem 36:21–31
Beard J (1906) The action of trypsin upon the living cells of jensen’s mouse-tumour. Br Med
J 1:140–141
Bernik MB (1973) Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition. J Clin Invest 52:823–834
Bhagat S, Agarwal M, Roy V (2013) Serratiopeptidase: a systematic review of the existing evidence. Int J Surg 11:209–217
Bijvoet AG, Van Hirtum H, Kroos MA, Van de Kamp EH, Schoneveld O, Visser P, Brakenhoff
JP, Weggeman M, van Corven EJ, Van der Ploeg AT, Reuser AJ (1999) Human acid alphaglucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type
II. Hum Mol Genet 8:2145–2153
Collen D, Van de Werf F (1993) Coronary thrombolysis with recombinant staphylokinase in
patients with evolving myocardial infarction. Circulation 87:1850–1853
Coppola A, Di Capua M, Di Minno MND, Di Palo M, Marrone E, Ieranò P, Arturo C, Tufano
A, Cerbone AM (2010) Treatment of hemophilia: a review of current advances and ongoing
issues. Journal of Blood Medicine 1:183–195
De Duve C (1966) The significance of lysosomes in pathology and medicine. Proceedings of the
Institute of Medicine of Chic 26:73–76
Ea HK, Richette HK (2012) Critical appraisal of the role of pegloticase in the management of gout.
Open Access Rheumatology: Research and Reviews 4:63–70
Elstein D (2011) Recent advances in treatment approaches to gaucher disease. Curr Pharm
Biotechnol 12:854–860
Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2002) Pegylated arginine deiminase (ADI-SS
PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and
in vivo. Cancer Res 62:5443–5450
Falabella AF (2006) Debridement and wound bed preparation. Dermatol Ther 19:317–325
Flohe L (1988) Superoxide dismutase for therapeutic use: clinical experience, dead ends and
hopes. Mol Cell Biochem 84:123–131
Gass J, Ehren J, Strohmeier G, Isaacs I, Khosla C (2005) Fermentation, purification, formulation,
and pharmacological evaluation of a prolyl endopeptidase from Myxococcus xanthus: implications for celiac sprue therapy. Biotechnol Bioeng 92:674–684
Goa KL, Henwood JM, Stolz JF, Langley MS, Clissold SP (1990) Intravenous streptokinase. A
reappraisal of its therapeutic use in acute myocardial infarction. Drugs 39:693–719
Hoffman M, Dargaud Y (2012) Mechanisms and monitoring of bypassing agent therapy. J Thromb
Haemost 10:1478–1485
Honig SC (2014) Intralesional collagenase in the treatment of Peyronie’s disease. Ther Adv Urol
6:47–53
2 Therapeutic Enzymes